Bromosporine is a broad spectrum inhibitor for bromodomains and as such will be very useful in elucidating further biological roles of reader domains as well as a tool for the validation of functional assays. Proteins that contain BRDs have been implicated in the development of a large variety of diseases, including various cancers, inflammatory diseases and neurological diseases and the therapeutic potential of bromodomain inhibition has been shown in several of these diseases, such as HIV, cancer and inflammation.
Chemical Name:
ethyl (3-methyl-6-(4-methyl-3-(methylsulfonamido)phenyl)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl)carbamate
Chemical Properties:
density: 1.46±0.1 g/cm3(Predicted)
pka: 6.21±0.46(Predicted)
Epigenetic Reader Domain Inhibitors Related Products:
ICG-001; (+)-JQ1; I-BET151; PFI-1; Molibresib; Apabetalone; C646; Curcumin; Birabresib; UNC1215; GSK6853; CPI-637; BI-9564; PFI-4; XMD8-92; MS436; CPI-203; KG-501; Mivebresib; GSK2801